BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. World J Hepatol 2015; 7(28): 2841-2848 [PMID: 26668696 DOI: 10.4254/wjh.v7.i28.2841]
URL: https://www.wjgnet.com/1948-5182/full/v7/i28/2841.htm
Number Citing Articles
1
Nabil Mohie Abdel-Hamid, Ahmed Wahid, Maiiada Hassan Nazmy, Marwa Abdel-Moniem Eisa. Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in RatsAsian Pacific Journal of Cancer Prevention 2016; 17(4): 1979 doi: 10.7314/APJCP.2016.17.4.1979
2
Satoshi Yamagiwa, Toru Ishikawa, Nobuo Waguri, Soichi Sugitani, Hiroto Wakabayashi, Shogo Ohkoshi, Takashi Tsukishiro, Toru Takahashi, Toshiaki Watanabe, Shuji Terai. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis CWorld Journal of Hepatology 2017; 9(5): 252-262 doi: 10.4254/wjh.v9.i5.252
3
Syed Manzoor Kadri, Marija Petkovic. Advances in Hepatology2021;  doi: 10.5772/intechopen.94879
4
Pietro Torre, Andrea Aglitti, Mario Masarone, Marcello Persico. Viral hepatitis: Milestones, unresolved issues, and future goalsWorld Journal of Gastroenterology 2021; 27(28): 4603-4638 doi: 10.3748/wjg.v27.i28.4603
5
Mohamed Aboushady, Ahmed Alwassief, Mohamed Abdelrazik, Dina Ziada, Hossam Shahba, Amr Elmestikawy, Ashraf Elbahrawy. Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual TherapyJournal of Interferon & Cytokine Research 2019; 39(9): 539 doi: 10.1089/jir.2019.0041